{"id":9042,"date":"2023-04-21T15:17:10","date_gmt":"2023-04-21T13:17:10","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=9042"},"modified":"2024-04-30T14:00:57","modified_gmt":"2024-04-30T12:00:57","slug":"sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/","title":{"rendered":"Sustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study"},"content":{"rendered":"
\n

Masahiro Sakai<\/a>\u00a01<\/a><\/sup>,\u00a0Koichi Hayashi<\/a>\u00a02<\/a><\/sup>,\u00a0Tomoyuki Ito<\/a>\u00a03<\/a><\/sup>,\u00a0Haruka Otani<\/a>\u00a03<\/a><\/sup>,\u00a0Yuya Mori<\/a>\u00a03<\/a><\/sup>,\u00a0Shinsuke Ito<\/a>\u00a01<\/a><\/sup>,\u00a0Keita Endo<\/a>\u00a01<\/a><\/sup>,\u00a0Hiroto Matsuda<\/a>\u00a04<\/a><\/sup>,\u00a0Kaede Yoshino<\/a>\u00a01<\/a><\/sup>,\u00a0Koichi Kitamura<\/a>\u00a01<\/a><\/sup>,\u00a0Eiji Kubota<\/a>\u00a05<\/a><\/sup>,\u00a0Yasuaki Motomura<\/a>\u00a06<\/a><\/sup>,\u00a0Yasuhiro Suzuki<\/a>\u00a07<\/a><\/sup>,\u00a0Shigeki Fujitani<\/a>\u00a08<\/a><\/sup>,\u00a0Toshihiko Suzuki<\/a>\u00a01<\/a><\/sup>Medicine (Baltimore).\u00a02023 Apr 21;102(16):e33368.\u00a0doi: 10.1097\/MD.0000000000033368.<\/p>\n<\/div>\n\n

\n

Although anti-tumor necrosis factor-\u03b1 monoclonal antibody biological preparations (BP) agents are widely used as an established treatment tool for refractory ulcerative colitis (UC), whether leukocytapheresis \/granulocytapheresis (L\/G-CAP) has similar beneficial impact on the disease activity remains undetermined. Furthermore, the costs defrayed for the treatment with these 2 modalities have not been compared. We retrospectively evaluated whether L\/G-CAP offered sustained beneficial effects over 2-year period. The patients who had moderately to severely active UC (Rachmilewitz clinical activity index (CAI) \u2267 5) and were treated with a series (10 sessions) of L\/G-CAP (n = 19) or BP (n = 7) as an add-on therapy to conventional medications were followed. Furthermore, the cost-effectiveness pertaining to the treatment with L\/G-CAP and BP was assessed over 12 months. At baseline, L\/G-CAP and BP groups manifested similar disease activity (CAI, L\/G-CAP; 7.0 [6.0-10.0], BP; 10.0 [6.0-10.0], P = .207). The L\/G-CAP and BP treatment suppressed the activity, with CAI 1 or less attained on day 180. When the L\/G-CAP group was dichotomized into L\/G-CAP-high and L\/G-CAP-low group based on CAI values (\u22653 or < 3) on day 365, CAI was gradually elevated in L\/G-CAP-high group but remained suppressed in L\/G-CAP-low group without additional apheresis for 2 years. Anemia was corrected more rapidly and hemoglobin levels were higher in BP group. The cost of the treatment with L\/G-CAP over 12 months was curtailed to 76% of that with BP (1.79 [1.73-1.92] vs 2.35 [2.29-3.19] million yen, P = .028). L\/G-CAP is as effective as BP in a substantial number of patients over 2 years. The cost for the treatment of UC favors L\/G-CAP although the correction of anemia may prefer BP. Thus, L\/G-CAP can effectively manage the disease activity with no additional implementation for 2 years although further therapeutic modalities might be required in a certain population with high CAI observed on day 365.<\/p>\n<\/div>\n\n

\n

Sustained effect of leukocytapheresis\/granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study – PubMed (nih.gov)<\/a><\/p>\n<\/div>\n\n

\n

Sustained effect of leukocytapheresis\/granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study – PMC (nih.gov)<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Masahiro Sakai\u00a01,\u00a0Koichi Hayashi\u00a02,\u00a0Tomoyuki Ito\u00a03,\u00a0Haruka Otani\u00a03,\u00a0Yuya Mori\u00a03,\u00a0Shinsuke Ito\u00a01,\u00a0Keita Endo\u00a01,\u00a0Hiroto Matsuda\u00a04,\u00a0Kaede Yoshino\u00a01,\u00a0Koichi Kitamura\u00a01,\u00a0Eiji Kubota\u00a05,\u00a0Yasuaki Motomura\u00a06,\u00a0Yasuhiro Suzuki\u00a07,\u00a0Shigeki Fujitani\u00a08,\u00a0Toshihiko Suzuki\u00a01Medicine (Baltimore).\u00a02023 Apr 21;102(16):e33368.\u00a0doi: 10.1097\/MD.0000000000033368. Although anti-tumor necrosis factor-\u03b1 monoclonal antibody biological preparations (BP) agents are widely used as an established treatment tool for refractory ulcerative colitis (UC), whether leukocytapheresis \/granulocytapheresis (L\/G-CAP) has similar beneficial impact on the disease activity […]<\/p>\n","protected":false},"template":"","scientific_tags":[751,92,626,424,109,148,627,305,306],"class_list":["post-9042","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-anemia","scientific_tags-anti-tnf","scientific_tags-cost-effective","scientific_tags-gma","scientific_tags-infliximab","scientific_tags-long-term-efficacy","scientific_tags-moderate-to-severe","scientific_tags-retrsopective","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37083800\/<\/a>\r\n\r\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10118317\/<\/a>"},"yoast_head":"\nSustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-\u03b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Masahiro Sakai\u00a01,\u00a0Koichi Hayashi\u00a02,\u00a0Tomoyuki Ito\u00a03,\u00a0Haruka Otani\u00a03,\u00a0Yuya Mori\u00a03,\u00a0Shinsuke Ito\u00a01,\u00a0Keita Endo\u00a01,\u00a0Hiroto Matsuda\u00a04,\u00a0Kaede Yoshino\u00a01,\u00a0Koichi Kitamura\u00a01,\u00a0Eiji Kubota\u00a05,\u00a0Yasuaki Motomura\u00a06,\u00a0Yasuhiro Suzuki\u00a07,\u00a0Shigeki Fujitani\u00a08,\u00a0Toshihiko Suzuki\u00a01Medicine (Baltimore).\u00a02023 Apr 21;102(16):e33368.\u00a0doi: 10.1097\/MD.0000000000033368. Although anti-tumor necrosis factor-\u03b1 monoclonal antibody biological preparations (BP) agents are widely used as an established treatment tool for refractory ulcerative colitis (UC), whether leukocytapheresis \/granulocytapheresis (L\/G-CAP) has similar beneficial impact on the disease activity […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-\u03b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-30T12:00:57+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/\",\"name\":\"Sustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-04-21T13:17:10+00:00\",\"dateModified\":\"2024-04-30T12:00:57+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-\u03b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/","og_locale":"fr_FR","og_type":"article","og_title":"Sustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study - Adacyte","og_description":"Masahiro Sakai\u00a01,\u00a0Koichi Hayashi\u00a02,\u00a0Tomoyuki Ito\u00a03,\u00a0Haruka Otani\u00a03,\u00a0Yuya Mori\u00a03,\u00a0Shinsuke Ito\u00a01,\u00a0Keita Endo\u00a01,\u00a0Hiroto Matsuda\u00a04,\u00a0Kaede Yoshino\u00a01,\u00a0Koichi Kitamura\u00a01,\u00a0Eiji Kubota\u00a05,\u00a0Yasuaki Motomura\u00a06,\u00a0Yasuhiro Suzuki\u00a07,\u00a0Shigeki Fujitani\u00a08,\u00a0Toshihiko Suzuki\u00a01Medicine (Baltimore).\u00a02023 Apr 21;102(16):e33368.\u00a0doi: 10.1097\/MD.0000000000033368. Although anti-tumor necrosis factor-\u03b1 monoclonal antibody biological preparations (BP) agents are widely used as an established treatment tool for refractory ulcerative colitis (UC), whether leukocytapheresis \/granulocytapheresis (L\/G-CAP) has similar beneficial impact on the disease activity […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-\u03b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/","og_site_name":"Adacyte","article_modified_time":"2024-04-30T12:00:57+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/","name":"Sustained effect of leukocytapheresis\/ granulocytapheresis versus anti-human TNF-\u03b1 monoclonal antibody on ulcerative colitis: A 2-year retrospective study - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-04-21T13:17:10+00:00","dateModified":"2024-04-30T12:00:57+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/sustained-effect-of-leukocytapheresis-granulocytapheresis-versus-anti-human-tnf-%ce%b1-monoclonal-antibody-on-ulcerative-colitis-a-2-year-retrospective-study\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/9042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=9042"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=9042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}